|
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer Clinical Trials Information presented on Clinical Trials Search isn't designed to be a substitute for certified healthcare advice, travels to or professional assistance using a genuine medical doctor. We are not physicians. Always confer with your dr. about Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer Clinical research trials and Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer medical trials happen in hundreds of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials usually measure the effectualness of new drugs. The intention of the studies / undertakings is to solve certain human healthcare questions. Clinical trials are a popular manner for mDs, government agencies, and private sector companies to locate treatments for all forms of circumstances, such as Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer. Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment choices before they are available to the general public. Some times the human subjects get treatment for free of charge, and sometimes they are paid for their time. Occasionally there is a cost for a Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer clinical trial. Participants frequently get the best healthcare available for their Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer condition. Risks are a reality, nonetheless, and can include extra or frequent physician trips, medical risks (possibly life-jeopardising), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "S" Clinical Trials Conditions > Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer  Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer
For Condition: Pancreatic Cancer
Status: Recruiting
Sponsor(s): M.D. Anderson Cancer Center ,
Synopsis: The goal of this clinical research study is to find the highest safe dose of the drug Bevacizumab that can be given in combination with chemoradiation for the treatment of pancreatic cancer. The effect that this combination treatment has on the tumor will also be studied.
Details: This study administers 50.4 Gy of radiation for unresectable pancreatic cancer with concurrent capecitabine and an experimental drug, Bevacizumab. The drug is an antiangiogenic agent (kills tumor blood vessels) and has been shown in preclinical models to enhance the antitumor effect of radiation and chemotherapy.
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: Inclusion: - Cytology or histologic proof of adenocarcinoma of the pancreatic head, body or tail prior to treatment. - Patients with nonmetastatic, unresectable, disease are eligible. - Patients with regional nodal disease are eligible. - Karnofsky performance status >/=70. - No upper age restriction. - Absolute granulocyte count >1,500 cells/mm3 and platelet count at least 100,000 cells/mm3. - Serum bilirubin less than 5mg/dl prior to the start of therapy with adequate biliary decompression. - Adequate bilateral renal function. - Serum creatinine <1.5 mg/dl. - Adequate liver function; Alanine aminotransferase (ALT)/aspartate aminotransferase (AST)
Total Enrollment: 48
Location and Contact Information:
University of Texas MDAnderson Cancer Center*Recruiting*
Houston, Texas, 77030
United States
RecruitingChristopher Crane 713-563-2340
Additional Information:
Study ID Numbers: ID02-146;
Study Start Date: September 2002
Record last reviewed: January 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00047710
Other Pancreatic CancerStudies:
1. Vaccine Therapy with Tumor Specific Mutated P53 or Ras Peptides Alone or in Combination with Cellular Immunotherapy with Peptide Activated Lymphocytes (PAL Cells) Along with Subcutaneous IL-2
2. Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer
3. Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
4. Gemcitabine, Herceptin and Radiation to Treat Cancer of the Pancreas
5. Gene Therapy in Treating Patients With Cancer
Related Studies:
Other Pancreatic Cancer Clinical Trials
Other Texas Clinical Trials
Other Houston Clinical Trials
Study of Combined RHUMAB VEGF and Capecitabine-based Chemoradiation for Patients with Locally Advanced Pancreatic Cancer
|
|
|
|
|
|
|
|
